
Navigating European Union Carbon Border Adjustment Mechanism (EU CBAM): Evaluating India’s Active Pharmaceutical Ingredient (API) Production Linked Incentive (PLI) Scheme
The global pharmaceutical sector for decades has been operating with a hyper-specialized and cost-driven business model. Under this approach, western pharmaceutical giants have used their capital to invest in high-margin research and development, patent acquisition and initial clinical design. Simultaneously, capital intensive, environmentally demanding, and low margin segments of manufacturing. Especially the synthesis of key starting materials (KSMs) and active pharmaceutical ingredients (APIs), were successively exported to developing Asian economies with lower overhead costs and more flexible regulatory frameworks.




